American Association for Cancer Research

sorry, we can't preview this file

23266066cir180654-sup-209004_2_supp_5302685_plw0tj.xlsx (423.55 kB)

Table S1 from Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity

Download (423.55 kB)
posted on 2023-04-04, 00:45 authored by Paula Kroon, Elselien Frijlink, Victoria Iglesias-Guimarais, Andriy Volkov, Marit M. van Buuren, Ton N. Schumacher, Marcel Verheij, Jannie Borst, Inge Verbrugge

RNA sequencing data on day 8 after RIT of sorted cell populations from irradiated and non-irradiated AT-3 tumors.


Dutch Cancer Society

Health Holland public-private partnership



To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected treatments. Here, we examined, in a poorly immunogenic mouse breast cancer model, the potential of antibody-based immunomodulation and conventional anticancer treatments to collaborate with anti–PD-1 treatment. One requirement to improve anti-PD-1–mediated tumor control was to promote tumor-specific cytotoxic T-cell (CTL) priming, which was achieved by stimulating the CD137 costimulatory receptor. A second requirement was to overrule PD-1–unrelated mechanisms of CTL suppression in the tumor microenvironment (TME). This was achieved by radiotherapy and cisplatin treatment. In the context of CD137/PD-1–targeting immunotherapy, radiotherapy allowed for tumor elimination by altering the TME, rather than intrinsic CTL functionality. Combining this radioimmunotherapy regimen with low-dose cisplatin improved CTL-dependent regression of a contralateral tumor outside the radiation field. Thus, systemic tumor control may be achieved by combining immunotherapy protocols that promote T-cell priming with (chemo)radiation protocols that permit CTL activity in both the irradiated tumor and (occult) metastases.